This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Globus Medical (GMED) is a Top-Ranked Growth Stock: Should You Buy?
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Reasons to Add The Cooper Companies Stock to Your Portfolio Now
by Zacks Equity Research
COO benefits from strength in its business segments. Its acquisitions are likely to drive the top line. However, a rise in selling, general and administrative expenses is concerning.
BAX Stock Falls Despite Q3 Earnings & Sales Beat, Margins Decline
by Zacks Equity Research
Baxter reports better-than-expected third-quarter results. However, the company's gross and operating margins contract. Shares fall.
SOLV Stock Gains as Q3 Earnings & Sales Beat Estimates, '24 View Up
by Zacks Equity Research
Solventum's top line reflects the favorable impact of pricing normalization. Organic growth is primarily driven by rising demand for MedSurg products. The higher EPS outlook looks promising.
MCK Stock Gains as Q2 Earnings & Sales Top Estimates, '25 EPS View Up
by Zacks Equity Research
McKesson's second-quarter fiscal 2025 results showcase growth in the U.S. Pharmaceutical segment. However, Medical Surgical Solutions suffers due to lower COVID-related sales.
Surmodics Q4 Earnings and Revenues Beat Estimates, Margin Down
by Zacks Equity Research
SRDX fiscal fourth-quarter results showcase growth in the medical device segment. The bottom line improves and beats the Zacks Consensus Estimate.
Accuray Q1 Earnings Meet Estimates, Sales Beat, Gross Margin Shrinks
by Zacks Equity Research
ARAY's first-quarter fiscal 2025 earnings meet estimates. Both the top and bottom lines deteriorate year over year.
GMED Q3 Earnings Top, '24 Guidance Raised, Stock Gains in Aftermarket
by Zacks Equity Research
Globus Medical delivers massive sales and earnings growth in the third quarter of 2024. However, margins contract.
Globus Medical (GMED) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
The headline numbers for Globus Medical (GMED) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Globus Medical (GMED) Beats Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Globus Medical (GMED) delivered earnings and revenue surprises of 27.69% and 3.44%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Insulet Stock Gains From Expansion Strategies, Innovation
by Zacks Equity Research
PODD continues to drive increased awareness for Omnipod through its direct-to-consumer advertising campaign.
QGEN Stock Set to Gain From FDA's Clearance of QIAstat-Dx Mini Panel
by Zacks Equity Research
QIAGEN wins FDA clearance for the QIAstat-Dx mini panel to improve precision in outpatient respiratory treatment.
Here's Why You Should Retain DGX Stock in Your Portfolio Now
by Zacks Equity Research
Investors feel optimistic about Quest Diagnostics' strength in Advanced Diagnostics. Robust base business volumes are also encouraging.
CAH Stocks Gains on Q1 Earnings & Sales Beat and Raised '25 EPS View
by Zacks Equity Research
Cardinal Health's first-quarter fiscal 2025 results benefit from solid Pharmaceutical and Specialty Solutions growth. However, OptumRx contract expiry hurts sales.
Boston Scientific Stock Gains From Market Expansion, Innovation
by Zacks Equity Research
BSX's Endoscopy business within MedSurg is gaining from strong worldwide demand for its broad range of gastrointestinal and pulmonary treatment options.
PAHC Stock Likely to Gain From Its Latest Acquisition of Zoetis
by Zacks Equity Research
Phibro successfully acquires Zoetis Inc.'s MFA portfolio and certain water-soluble products.
Gear Up for Globus Medical (GMED) Q3 Earnings: Wall Street Estimates for Key Metrics
by Zacks Equity Research
Beyond analysts' top -and-bottom-line estimates for Globus Medical (GMED), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended September 2024.
Avanos Q3 Earnings Meet Estimates, Sales Miss, Gross Margin Contracts
by Zacks Equity Research
Strength in AVNS' Digestive Health segment drives its third-quarter performance
CONMED Beats on Q3 Earnings, Misses on Sales, Lowers '24 Sales View
by Zacks Equity Research
CNMD's Q3 earnings beat estimates on the back of higher revenues and lower costs and expenses.
GE HealthCare Q3 Earnings Beat Estimates, Sales Meet, Net Margin Up
by Zacks Equity Research
GEHC's third-quarter results witness declining segmental revenues in imaging and ultrasound, offset by strong Pharmaceutical Diagnostics performance. The bottom line improves on better pricing.
Positive Trial Data on Symplicity RDN System Likely to Support MDT Stock
by Zacks Equity Research
Medtronic announces new long-term favorable data for its Symplicity Spyral RDN system, which has undergone a SPYRAL HTN-ON MED clinical trial.
Inari Medical Q3 Earnings Miss Estimates, Revenues Increase Y/Y
by Zacks Equity Research
NARI's third-quarter results witness an increase in revenues with dismal bottom-line performance. Gross margins contract while the company continues to incur operating losses.
TransMedics Stock Falls as Q3 Earnings & Sales Miss Estimates
by Zacks Equity Research
TMDX's third-quarter revenues increase with the utilization of the OCS across all three organs and additional revenues generated by its logistics services. Gross margin contracts.
ABT's New Trial on Advanced Heart Failure Outcomes Set to Boost Stock
by Zacks Equity Research
Abbott initiates the TEAM-HF trial to improve outcomes for advanced heart failure.
Is GMED Stock a Smart Addition to Your Portfolio Right Now?
by Zacks Equity Research
Globus Medical's synergistic merger with NuVasive and a cadence of product launches bring optimism to investors.